David Dongkyung Kim1, Huda Alghefari2, Mary Jenkins1, Lee-Cyn Ang1,2, Stephen H Pasternak1,3. 1. Department of Clinical Neurological Sciences Western University London Ontario Canada. 2. Department of Pathology and Laboratory Medicine Western University London Ontario Canada. 3. Molecular Brain Research Group, Robarts Research Institute Western University London Ontario Canada.
Abstract
BACKGROUND: Perry syndrome is a rare genetic parkinsonian disorder with TAR DNA binding protein 43 (TDP-43) pathology clinically presenting with parkinsonism, neuropsychiatric features, weight loss, and central hypoventilation. As respiratory complications are often the cause of death, studies likely show the early stage of the neurodegenerative process. Because of the rarity of this condition, few studies exist, and each case provides insight into pathological findings in this neurodegenerative condition. OBJECTIVE: To study the clinical and pathological correlations of an autopsy case of Perry syndrome. METHODS: The patient was a woman in her 50s with Perry syndrome and a DCTN1 gene mutation. Between October 2016 and July 2019, she underwent postmortem and pathological examination at University Hospital in London, Ontario, Canada. Data were obtained through clinical pathological examination. RESULTS: Microscopy showed significant neuronal loss with pigmentary incontinence and gliosis in the substantia nigra. There was no atrophy elsewhere, including the frontal and cingulate cortex. Intraneuronal cytoplasmic TDP-43 inclusions and neurites were noticed in a moderate number in the substantia nigra and midbrain and were sparsely noticed in the basal ganglia, thalamus, thoracic motor neuron, posterior nucleus of the hypothalamus, and rostral ventral medulla. β-Amyloid, Lewy body, and tau pathologies were absent. Rare axonal swelling was identified at the rostral ventrolateral medulla. CONCLUSIONS AND RELEVANCE: This study confirms that Perry syndrome is characterized by TDP-43 pathology with absent Lewy bodies or tau pathology. These findings support the hypothesis of dysfunctional neurons in the medulla and hypothalamus, which may respectively correlate to the clinical symptoms of hypoventilation and weight loss in Perry syndrome.
BACKGROUND: Perry syndrome is a rare genetic parkinsonian disorder with TAR DNA binding protein 43 (TDP-43) pathology clinically presenting with parkinsonism, neuropsychiatric features, weight loss, and central hypoventilation. As respiratory complications are often the cause of death, studies likely show the early stage of the neurodegenerative process. Because of the rarity of this condition, few studies exist, and each case provides insight into pathological findings in this neurodegenerative condition. OBJECTIVE: To study the clinical and pathological correlations of an autopsy case of Perry syndrome. METHODS: The patient was a woman in her 50s with Perry syndrome and a DCTN1 gene mutation. Between October 2016 and July 2019, she underwent postmortem and pathological examination at University Hospital in London, Ontario, Canada. Data were obtained through clinical pathological examination. RESULTS: Microscopy showed significant neuronal loss with pigmentary incontinence and gliosis in the substantia nigra. There was no atrophy elsewhere, including the frontal and cingulate cortex. Intraneuronal cytoplasmic TDP-43 inclusions and neurites were noticed in a moderate number in the substantia nigra and midbrain and were sparsely noticed in the basal ganglia, thalamus, thoracic motor neuron, posterior nucleus of the hypothalamus, and rostral ventral medulla. β-Amyloid, Lewy body, and tau pathologies were absent. Rare axonal swelling was identified at the rostral ventrolateral medulla. CONCLUSIONS AND RELEVANCE: This study confirms that Perry syndrome is characterized by TDP-43 pathology with absent Lewy bodies or tau pathology. These findings support the hypothesis of dysfunctional neurons in the medulla and hypothalamus, which may respectively correlate to the clinical symptoms of hypoventilation and weight loss in Perry syndrome.
Authors: Joy Mitra; Erika N Guerrero; Pavana M Hegde; Nicole F Liachko; Haibo Wang; Velmarini Vasquez; Junling Gao; Arvind Pandey; J Paul Taylor; Brian C Kraemer; Ping Wu; Istvan Boldogh; Ralph M Garruto; Sankar Mitra; K S Rao; Muralidhar L Hegde Journal: Proc Natl Acad Sci U S A Date: 2019-02-15 Impact factor: 11.205
Authors: Takuya Konno; Owen A Ross; Hélio A G Teive; Jarosław Sławek; Dennis W Dickson; Zbigniew K Wszolek Journal: Parkinsonism Relat Disord Date: 2017-06-12 Impact factor: 4.891
Authors: Yoshio Tsuboi; Dennis W Dickson; Kazuki Nabeshima; Ann M Schmeichel; Zbigniew K Wszolek; Tatsuo Yamada; Eduardo E Benarroch Journal: Acta Neuropathol Date: 2007-06-19 Impact factor: 17.088
Authors: Christian Wider; Justus C Dachsel; Matthew J Farrer; Dennis W Dickson; Yoshio Tsuboi; Zbigniew K Wszolek Journal: J Neurol Sci Date: 2009-09-04 Impact factor: 3.181
Authors: Christian Wider; Dennis W Dickson; A Jon Stoessl; Yoshio Tsuboi; Françoise Chapon; Ludwig Gutmann; Bernard Lechevalier; Donald B Calne; David A Personett; Mary Hulihan; Jennifer Kachergus; Rosa Rademakers; Matthew C Baker; Linda L Grantier; O K Sujith; Laura Brown; Susan Calne; Matthew J Farrer; Zbigniew K Wszolek Journal: Parkinsonism Relat Disord Date: 2008-08-23 Impact factor: 4.891